Today's options market carries a clear political edge. TSLA headlines are driven by California Governor Gavin Newsom's public jab at Elon Musk. He suggested Tesla and SpaceX "would be nothing" without the state. That kind of headline accelerates options activity. TSLA's expiry chain runs to 26 dates — with near-term weeklies packed out through June. Short interest sits at just 2.7% of free float. The options crowd is not betting on a squeeze. They are watching headlines.
Pharma is the sharper story today. JNJ received a new FDA approval for TREMFYA in psoriatic arthritis. Its options chain shows active interest through August, with short interest at a lean 0.9% of free float. Call-side pressure typically follows FDA approvals of this type.
PFE meanwhile sealed a partnership with Innovent to develop 12 new cancer treatments. Pfizer's options run through August 21. Short interest is 2.7% of free float. Availability is extremely high — over 7,600% of SI. Shorts are not crowded here, but the options market may be pricing in pipeline optionality.
NVDA maintains the longest options calendar of any name tracked today. Expiries extend to September 2026. Its $5.1 trillion market cap and 1.3% SI make it a low-conviction short. The September expiry signals traders are hedging multi-month positions around AI capex cycles.
WYNN made CNBC's final trades segment — a signal of near-term options interest from retail flow desks. Wynn options are thinner but directional bets around gaming revenue remain active.
This article is not financial advice.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
